Clopidogrel/omeprazole - Cogentus Pharmaceuticals

Drug Profile

Clopidogrel/omeprazole - Cogentus Pharmaceuticals

Alternative Names: CGT-2168

Latest Information Update: 23 Mar 2010

Price : $50

At a glance

  • Originator Cogentus Pharmaceuticals
  • Class 2 pyridinylmethylsulfinylbenzimidazoles; Antiplatelets; Antiulcers; Gastric antisecretories; Thiophenes
  • Mechanism of Action Platelet activating factor inhibitors; Platelet ADP receptor antagonists; Platelet aggregation inhibitors; Proton pump inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Suspended Ischaemic heart disorders; Peptic ulcer

Most Recent Events

  • 17 Mar 2010 Drug interactions data from two clinical trials released by the European Medicines Agency
  • 03 Sep 2008 Pharmacokinetics data from a phase I trial in healthy volunteers presented at the Congress of the European Society of Cardiology (ESC-2008)
  • 16 Jun 2008 Phase-III clinical trials in Peptic ulcer in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top